ABCL News and Press, AbCellera Biologics Inc. From 07/19/23

2023-07-19 01:26:24 ET Summary AbCellera Biologics, a multinational company focused on antibody drug development, experienced a drop in revenue due to reduced demand for its COVID-19 antibody treatments. Despite financial setbacks, ABCL remains operational and continues to form pa...

AbCellera (Nasdaq: ABCL) will announce its second quarter 2023 financial results on Thursday, August 3, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link ...

2023-06-29 13:31:15 ET Summary Shares of antibody discovery platform concern OmniAb have recovered marginally from their SPAC-birthed debut, when they were down 61% in their first day of regular-way trading. With three approved antibody therapies and 24 in the clinic, the company&...

2023-06-27 18:45:00 ET Early investors in Canadian biotech stock BELLUS Health ( TSX:BLU ) could be ecstatic right now after a fine 75.5% rally in BLU stock year to date. The bullish run was ensued after global pharmaceuticals giant GSK offered to acquire all BELLUS stock at...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time (4:20 p.m. Eastern Time). A live audio webcast of the presentat...

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

CA$701 million co-investment to strengthen capabilities and infrastructure for drug development, manufacturing, and clinical research in Canada AbCellera to build state-of-art facilities and technologies capable of developing new antibody medicines from a disease target to the completion ...

2023-05-06 00:42:48 ET Summary AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive quarter under the surface, reporting progress on m...

2023-05-05 00:30:31 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q1 2023 Earnings Call May 04, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q1 2023 Earnings Call...